Tokai University - Japan
Author Profile
Orcid
Scopus
🎓 Early Academic Pursuits
Prof. Masako Shomura’s academic journey began at Chiba University, where she earned her B.S. in Nursing (1989-1993). Driven by a desire to advance her knowledge in healthcare, she pursued an M.A. in Nursing (2000-2002) at Chiba University and subsequently a Ph.D. in Nursing at Tokyo Medical and Dental University (2004-2007). Her dissertation, titled “Construction of Illness Experience Model for Patients with Intractable Primary Hepatocellular Cancer and Research on Oncology Palliative Care Nursing,” established the foundation for her lifelong dedication to ONCOLOGY NURSING, specifically addressing the palliative needs of patients with liver cancer.
💼 Professional Endeavors
Prof. Shomura began her professional career as a Staff Nurse in the GI unit at Tokai University Hospital (1993-1996). Her clinical experience fueled her passion for patient-centered care and led her to an academic role as Assistant Professor at Tokai University School of Health Sciences (1996-2000). Over the years, Prof. Shomura continued to advance through various roles, including a position as a Home Care Nurse at Morinosato Hospital (2002-2004) and later as Associate Professor at Tokai University School of Medicine (2007-2010). In 2020, she was appointed as a full Professor, where she continues to innovate in ONCOLOGY NURSING and SUPPORTIVE AND PALLIATIVE CARE.
🔬 Contributions and Research Focus
Prof. Shomura’s research is deeply embedded in ONCOLOGY NURSING and the development of supportive care programs for liver cancer patients. She has secured multiple grants, including the Grant-in-Aid for Scientific Research (B) for developing an early detection system for immune-related adverse events in patients with liver cancer (2022-2025). Her pioneering studies include interventions that promote self-management among advanced cancer patients undergoing targeted therapy and programs to reduce psychosocial distress in cancer patients and their families. Prof. Shomura’s work has consistently contributed to innovative nursing approaches aimed at enhancing patient quality of life and treatment efficacy.
🌍 Impact and Influence
Prof. Shomura’s influence within ONCOLOGY NURSING extends internationally, as evidenced by her award-winning presentations at prominent conferences, including the American Association for the Study of Liver Diseases and the International Society of Nurses in Cancer Care. Her work on the relationship between physical activity, quality of life, and self-efficacy in cancer patients has been instrumental in advancing nursing interventions that improve cancer care outcomes. Prof. Shomura’s commitment to evidence-based care has made her a respected figure among healthcare professionals globally.
🏆Academic Cites
Prof. Shomura’s research is highly cited in studies focused on ONCOLOGY NURSING, particularly in areas involving supportive and palliative care for cancer patients. Her findings on illness experience models and nursing intervention programs for liver cancer patients are frequently referenced in academic literature, further demonstrating the significant impact her work has had in the field. Her research has influenced subsequent studies on cancer patient care, particularly in terms of self-management and quality-of-life interventions.
🌟 Legacy and Future Contributions
Looking ahead, Prof. Shomura is dedicated to expanding her research on nursing interventions aimed at improving cancer treatment efficacy. Her future projects include developing a physical activity intervention program specifically for elderly or overweight cancer survivors, addressing an emerging need in supportive care. Prof. Shomura’s legacy in ONCOLOGY NURSING will continue to shape patient care practices, promoting holistic and empathetic approaches that improve both survival and quality of life for patients worldwide. Her work sets a benchmark for future nursing research and clinical practices, ensuring that her contributions will be felt for generations to come.
📝Notable Publication
📝Hypothyroidism is a predictive factor for better clinical outcomes in patients with advanced hepatocellular carcinoma undergoing lenvatinib therapy
Authors: M. Shomura, H. Okabe, E. Sato, K. Anzai, T. Kagawa
Journal: Cancers
Year: 2020
Citations: 19
📝Longitudinal alterations in health-related quality of life and its impact on the clinical course of patients with advanced hepatocellular carcinoma receiving sorafenib treatment
Authors: M. Shomura, T. Kagawa, H. Okabe, S. Takahira, T. Mine
Journal: BMC Cancer
Year: 2016
Citations: 13
📝Skin toxicity predicts efficacy to sorafenib in patients with advanced hepatocellular carcinoma
Authors: M. Shomura, T. Kagawa, K. Shiraishi, J. Koizumi, T. Mine
Journal: World Journal of Hepatology
Year: 2014
Citations: 32
📝Complete response after short-term sorafenib treatment in a patient with lymph node metastasis of hepatocellular carcinoma
Authors: H. Mizukami, T. Kagawa, Y. Arase, K. Tobita, T. Mine
Journal: Case Reports in Oncology
Year: 2012
Citations: 15